One of these products is a combination of FSH and LH hormones that is obtained from the urine of postmenopausal women. BRAVELLE ® can be administered by subcutaneous (SC) or intramuscular (IM) injections and is used for women undergoing ovulation induction and multiple follicular development in those who are able to produce and release eggs (ovulate). BRAVELLE ® is a highly purified preparation of human follicle FSH, containing 75 IUs FSH with 2% luteinizing hormone (LH) activity. BRAVELLE ® stimulates eggs to mature in women whose ovaries are basically healthy but are unable to develop eggs. It is not used by women who suffer from ovarian failure.
Preparations of follicle-stimulating hormone (FSH) mainly include those derived from the urine of menopausal women, as well as recombinant preparations. The recombinant preparations are more pure and more easily administered, but they are more expensive. The urinary preparations are equally effective and less expensive, but are not as convenient to administer as they are available in vials versus injection pens. One study reported that users of the purified urinary FSH preparation Bravelle experienced less injection site pain compared to the recombinant preparation Follistim.